Highest-materiality recent filing
West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair
Michel Lagarde appointed President & CEO of West Pharmaceutical, effective Aug 31, 2026.
Cybersecurity incident detected on May 4, 2026 involved data exfiltration and system encryption.
Incident detected May 4, 2026; determined material on May 7, 2026.
West Pharma Q1 beats: revenue up 21%, adj. EPS up 47%; raises FY26 guidance
Net sales of $844.9M (+21% reported, +15.3% organic); GAAP EPS $1.92 (+56%), adjusted EPS $2.13 (+47%)
CEO Eric M. Green to retire; West reaffirms 2026 guidance
Eric M. Green informed Board on March 6, 2026 of plan to retire as President, CEO and Chair after successor is hired, expected H2 2026.
West Pharma Q4 adj EPS $2.04, +12.1% YoY; guides FY2026 $7.85-$8.20
Q4 net sales $805M (+7.5% reported, +3.3% organic); HVP Components $389.8M (+20.3%, +15.1% organic).
West Pharma Q3 net sales $804.6M (+7.7%), adjusted EPS $1.96; raises FY guidance
Proprietary Products HVP Components net sales $390M, +16.3% YoY, driven by GLP-1 products and HVP conversion.
West Pharma beats Q2, raises FY 2025 guidance; declares Q4 dividend
Net sales $766.5M (+9.2% YoY); diluted EPS $1.82 vs $1.51; adjusted EPS $1.84 vs $1.52.
West Pharma shareholders approve amended 2016 Omnibus Plan; share reserve increased by 2M
Shareholders approved amendment effective May 6, 2025; total share reserve increased to 7,500,000 from 5,500,000.
West Q1 sales $698M (+0.4%), adj. EPS $1.45; raises FY2025 net sales and adj. EPS guidance
Net sales $698.0M (+0.4% reported, +2.1% organic); reported EPS $1.23 vs $1.55 YoY; adj. EPS $1.45 vs $1.56 YoY.
West Pharma CFO Birkett to retire; Campbell named Chief Proprietary Segment Officer
CFO Bernard Birkett informed West of intention to retire; search for successor initiated; will remain until transition and then advisory role through Dec 31, 2025.
West Pharma Q4 net sales $748.8M (+2.3%), adj EPS $1.82; FY25 guidance $6.00-$6.20 EPS
Q4 organic net sales grew 3.3%, driven by Proprietary Products (+4.5%) led by self-injection devices.
West Pharma Q3 EPS $1.85 (down from $2.14); raises FY2024 guidance, boosts dividend 5%
Q3 net sales $746.9M flat YoY; reported EPS $1.85 vs $2.14; adjusted EPS $1.85 vs $2.16.
West Pharma Q2 net sales miss; slashes FY 2024 EPS guidance by over $1.20
Q2 net sales $702.1M, down 6.9% YoY; reported diluted EPS $1.51 vs $2.06; adj. EPS $1.52 vs $2.11.
West enters $130M incremental term loan to refinance existing debt and notes
On July 2, 2024, West Pharmaceutical Services entered a Third Amendment to its Credit Agreement, establishing a $130.0 million incremental term loan.
West Pharma Q1 sales $695.4M (-3%) adj EPS $1.56 (-21%), raises full-year adj EPS guidance
Reported-diluted EPS $1.55, down 16.2% YoY; adjusted-diluted EPS $1.56, down 21.2%.
West Pharma Q4 adj EPS flat YoY at $1.83; FY24 adj EPS guidance $7.50-$7.75 vs $8.08 in FY23
Q4 net sales $732.0M (+3.3% YoY); full-year net sales $2.950B (+2.2% YoY).
West Pharmaceutical extends butyl polymer supply agreement with ExxonMobil through 2028
Amendment secures supply of butyl polymers, a key raw material for pharmaceutical packaging, from 2024 to 2028.
West Pharma Q3: adj EPS $2.16, rev $747.4M; raises FY adj EPS outlook to $7.95-8.00
Q3 net sales $747.4M, +8.8% YoY; organic growth 5.7%.
West Pharma Q2 net sales $753.8M (-2.3%), adjusted EPS $2.11; raises FY2023 guidance
Reported Q2 diluted EPS of $2.06; adjusted diluted EPS of $2.11, down from $2.47 YoY.
West Pharma reports Q1 2023 net sales $716.6M, adjusted EPS $1.98; raises full-year guidance
Net sales $716.6M (down 0.5% YoY); organic sales growth 2.3%. Reported diluted EPS $1.85 (down 19.2%); adjusted diluted EPS $1.98 (down 13.9%).
West Pharma Q4 revenue -3% to $708.7M, adj. EPS $1.77; FY23 guidance $7.25-$7.40, $1B buyback
Q4 net sales $708.7M (-3.0% reported, +2.6% organic); reported EPS $1.36, adjusted EPS $1.77.
West Pharma Q3 adj. EPS $2.03; cuts FY2022 guidance; raises dividend 5.6%
Net sales $686.9M (-2.8% reported, +4.3% organic); HVP net sales mid-single digit organic growth.
West Pharma Q2 net sales $771M (+6.6%); cuts FY2022 guidance on FX and COVID decline
Q2 net sales $771.3M (+6.6% reported, +13.1% organic); reported EPS $2.48, adjusted EPS $2.47.
West Pharma Q1 net sales $720M (+7.4%), adj. EPS $2.30; raises FY2022 adj. EPS guidance
Net sales $720.0M (+7.4% YoY); organic sales growth 11.0%.
Chairman Patrick Zenner to retire; CEO Eric Green becomes Chair; Lead Independent Director appointed
Patrick Zenner to retire from Board at May 24, 2022 Annual Meeting after 20 years; no disagreement with Company.
West Pharma reports record FY2021 sales $2.832B (+32%), guides FY2022 EPS $9.20-$9.35
Q4 net sales $730.8M (+26%), organic +28.3%; full-year sales $2.832B (+31.9%), organic +29.4%.
As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.
As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.
On June 1, 2026, the Company announced the appointment of Michel Lagarde as President and Chief Executive Officer of the Company, effective August 31, 2026 (the “Start Date”), to replace Mr. Green in those roles.
As of the Start Date, Lead Independent Director Robert F. Friel will become Chair of the Board.
On April 24, 2025, the Company announced that it had appointed Shane Campbell to serve as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025
On April 22, 2025, Mr. Bernard Birkett notified West Pharmaceutical Services, Inc. (the “Company”) of his intention to retire as Senior Vice President & Chief Financial Officer later this year.
On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, departed from the Company effective that same date.
On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, has departed the Company, effective the same day.
On October 1, 2024, Silji Abraham, Senior Vice President & Chief Technology Officer of West Pharmaceutical Services, Inc. (the “Company”), notified the Company that he intends to resign, effective December 31, 2024, to pursue other interests.
Effective May 1, 2024, Mr. Birkett’s title will be solely Chief Financial Officer (“CFO”), where he will retain financial oversight for both Business Segments, operational oversight of our strategic sourcing function and be involved in key operational issues together with other members of our executive team.
On July 26, 2022, West Pharmaceutical Services, Inc. (the "Company") elected Stephen Lockhart, M.D., Ph.D., to its Board of Directors (the "Board") as its newest member.
After six years of dedicated service, the Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo, has announced his resignation to pursue other interests, with a departure date of July 2022.
Max materiality 1.00 · Median 0.60 · Most common event earnings